Antiviral Strategies pp 299-320

Part of the Handbook of Experimental Pharmacology book series (HEP, volume 189)

Antiviral Resistance and Impact on Viral Replication Capacity: Evolution of Viruses Under Antiviral Pressure Occurs in Three Phases

Chapter

Resistance development is a major obstacle to antiviral therapy, and all active antiviral agents have shown to select for resistance mutations. Aspects of antiviral resistance development are discussed for specific compounds or drug classes in the previous chapters, while this chapter provides an overview regarding the evolution of different viruses (HIV, HBV, HCV, and Influenza) under pressure of antiviral therapy. Virus replication is an error prone process resulting in a large number of variants (quasispecies) in patients. Resistance evolution under suboptimal therapy can be schematically distinguished into three phases. (1) preexisting variants less sensitive to the respective drug are selected from the quasispecies population, (2) outgrowing variants acquire additional mutations increasing their resistance, and (3) compensatory mutations accumulate to overcome the generally reduced replica-tive capacity of resistant variants. Successful therapy should be aimed at suppression of all existing viral variants, thus preventing selection of minority species and their subsequent evolution. This implies that the amount of mutations required for first escape to the viral regimen (genetic barrier) should be larger than the expected number of mutations present in viruses in the quasispecies. Accordingly, combination therapy can achieve complete inhibition of replication for most HIV, HBV, and Influenza infected patients without resistance development. However, resistant viruses can become selected under circumstances of suboptimal antiviral therapy and these resistant viruses can be transmitted. Proper use of drugs and worldwide monitoring for the presence and spread of drug resistant viruses are therefore of utmost importance.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abed Y, Goyette N, Boivin G (2005) Generation and characterization of recombinant influenza A (H1N1) viruses harboring amantadine resistance mutations. Antimicrob Agents Chemother 49:556–559PubMedCrossRefGoogle Scholar
  2. Abed Y, Baz M, Boivin G (2006) Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antivir Ther 11:971–976PubMedGoogle Scholar
  3. Aoki FY, Boivin G, Roberts N (2007) Influenza virus susceptibility and resistance to oseltamivir. Antivir Ther 12:603–616PubMedGoogle Scholar
  4. Arion D, Kaushik N, McCormick S, Borkow G, Parniak MA (1998) Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochem 37:15908–15917CrossRefGoogle Scholar
  5. Bartholomeusz A, Locarnini S (2006) Hepatitis B virus mutations associated with antiviral therapy J Med Virol 78 Suppl 1:S52–S55PubMedCrossRefGoogle Scholar
  6. Borroto-Esoda K, Miller MD, Arterburn S (2007) Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. J Hepatol 47:492–498CrossRefGoogle Scholar
  7. Bright RA, Medina MJ, Xu X, Perez-Oronoz G, Wallis TR, Davis XM, Povinelli L, Cox NJ,Klimov AI (2005) Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366:1175–1181PubMedCrossRefGoogle Scholar
  8. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI (2006) Adamantane resistance among influenza A viruses isolated early during the 2005–2006 influenza season in the United States. JAMA 295:891–894PubMedCrossRefGoogle Scholar
  9. Coffin JM (1995) HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483–489PubMedCrossRefGoogle Scholar
  10. Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, Walsh A, Fang J, Hsu M, Mazzucco C, Eggers B, Zhang S, Plym M, Klesczewski K, Tenney DJ (2006) Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 44:1656–1665PubMedCrossRefGoogle Scholar
  11. Das K, Xiong X, Yang H, Westland CE, Gibbs CS, Sarafianos SG, Arnold E (2001) Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol 75:4771–4779PubMedCrossRefGoogle Scholar
  12. De FR, Migliaccio G (2005) Challenges and successes in developing new therapies for hepatitis C. Nature 436:953–960CrossRefGoogle Scholar
  13. de Jong MD, Schuurman R, Lange JMA, Boucher CAB (1996) Replication of a pre-existing resistant HIV-1 subpopulation in vivo after introduction of a strong selective drug pressure. Antivir Ther 1:33–41PubMedGoogle Scholar
  14. de Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, Nguyen VC, Bach VC, Phan TQ, Do QH, Guan Y, Peiris JS, Tran TH, Farrar J (2005) Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 353:2667–2672PubMedCrossRefGoogle Scholar
  15. De Meyer S, Azijn H, Surleraux D, Jochmans D, Tahri A, Pauwels R, Wigerinck P, de Bethune MP (2005) TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 49:2314–2321PubMedCrossRefGoogle Scholar
  16. Delaney WE, Yang H, Westland CE, Das K, Arnold E, Gibbs CS, Miller MD, Xiong S (2003) The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 77:11833–11841PubMedCrossRefGoogle Scholar
  17. Delwart EL, Sheppard HW, Walker BD, Goudsmit J, Mullins JI (1994) Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays. J Virol 68:6672–6683PubMedGoogle Scholar
  18. Delwart EL, Pan H, Neumann A, Markowitz M (1998) Rapid, transient changes at the env locus of plasma Human Immunodeficiency Virus type 1 populations during the emergence fo protease inhibitor resistance. J Virol 72:2416–2421PubMedGoogle Scholar
  19. Dierynck I, De WM, Gustin E, Keuleers I, Vandersmissen J, Hallenberger S, Hertogs K (2007) Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier. J Virol 81:13845–13851PubMedCrossRefGoogle Scholar
  20. Domingo E, Menendez Arias L, Quinones-Mateu ME, Holguin A, Gutierrez-Rivas M, Martinez MA, Quer J, Novella IS, Holland JJ (1997) Viral quasispecies and the problem of vaccine-escape and drug-resistant mutants. Prog Drug Res 48:99–128PubMedGoogle Scholar
  21. Doyon L, Croteau G, Thibeault D, Poulin F, Pilote L, Lamarre D (1996) Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol 70:3763–3769PubMedGoogle Scholar
  22. Doyon L, Payant C, Brakier Gingras L, Lamarre D (1998) Novel Gag-Pol frameshift site in human immunodeficiency virus type 1 variants resistant to protease inhibitors. J Virol 72:6146–6150PubMedGoogle Scholar
  23. Durantel D, Brunelle MN, Gros E, Carrouee-Durantel S, Pichoud C, Villet S, Trepo C, Zoulim F (2005) Resistance of human hepatitis B virus to reverse transcriptase inhibitors: from genotypic to phenotypic testing. J Clin Virol 34 Suppl 1:S34–S43PubMedCrossRefGoogle Scholar
  24. Ferraris O, Lina B (2008) Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. J Clin Virol 41:13–19PubMedCrossRefGoogle Scholar
  25. Gallant JE, Rodriguez AE, Weinberg WG, Young B, Berger DS, Lim ML, Liao Q, Ross L, Johnson J, Shaefer MS (2005) Early virologic nonresponse to tenofovir, abacavir, and lamivu-dine in HIV-infected antiretroviral-naive subjects. J Infect Dis 192:1921–1930PubMedCrossRefGoogle Scholar
  26. Garcia-Lerma JG, MacInnes H, Bennett D, Weinstock H, Heneine W (2004) Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine. J Virol 78:7545–7552PubMedCrossRefGoogle Scholar
  27. Gubareva LV, Kaiser L, Matrosovich MN, Soo-Hoo Y, Hayden FG (2001) Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis 183:523–531PubMedCrossRefGoogle Scholar
  28. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Ma J, Brosgart CL, Borroto-Esoda K, Arterburn S, Chuck SL (2006) Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131:1743–1751PubMedCrossRefGoogle Scholar
  29. Hayden FG (2006) Antivirals for influenza: historical perspectives and lessons learned. Antiviral Res 71:372–378PubMedCrossRefGoogle Scholar
  30. Hayden FG, Belshe RB, Clover RD, Hay AJ, Oakes MG, Soo W (1989) Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med 321:1696–1702PubMedGoogle Scholar
  31. Hazuda DJ, Miller MD, Nguyen BN, Zhao J, for the P005 study team (2007) Resistance to HIV- integrase inhibitor raltegravir: analysis of protocol 005, a Phase II study in patients with triple-class resistant HIV-1 infection. Antivir Ther 12:S10Google Scholar
  32. Herlocher ML, Truscon R, Elias S, Yen HL, Roberts NA, Ohmit SE, Monto AS (2004) Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis 190:1627–1630PubMedCrossRefGoogle Scholar
  33. Hertogs K, de Bethune MP, Miller V, Ivens T, Schel P, Van Cauwenberge A, Van Den Eynde C, Van Gerwen V, Azijn H, Van Houtte M, Peeters F, Staszewski S, Conant M, Bloor S, Kemp S, Larder B, Pauwels R (1998) A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 42:269–276PubMedCrossRefGoogle Scholar
  34. Howe AY, Cheng H, Thompson I, Chunduru SK, Herrmann S, O'Connell J, Agarwal A, Chopra R, Del Vecchio AM (2006) Molecular mechanism of a thumb domain hepatitis C virus nonnucleo-side RNA-dependent RNA polymerase inhibitor. Antimicrob Agents Chemother 50:4103–4113PubMedCrossRefGoogle Scholar
  35. Hsiou Y, Ding J, Das K, Clark AD Jr, Boyer PL, Lewi P, Janssen PA, Kleim JP, Rosner M, Hughes SH, Arnold E (2001) The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance. J Mol Biol 309:437–445PubMedCrossRefGoogle Scholar
  36. Huigen MC, van Ham PM, de GL, Kagan RM, Boucher CA, Nijhuis M (2008) Identification of a novel resistance (E40F) and compensatory (K43E) substitution in HIV-1 reverse transcriptase. Retrovirology 5:20PubMedCrossRefGoogle Scholar
  37. Ives JA, Carr JA, Mendel DB, Tai CY, Lambkin R, Kelly L, Oxford JS, Hayden FG, Roberts NA (2002) The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res 55:307–317PubMedCrossRefGoogle Scholar
  38. Jourdain G, Ngo-Giang-Huong N, Le CS, Bowonwatanuwong C, Kantipong P, Leechanachai P, Ariyadej S, Leenasirimakul P, Hammer S, Lallemant M (2004) Intrapartum exposure to nevi- rapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 351:229–240PubMedCrossRefGoogle Scholar
  39. Kantor R (2006) Impact of HIV-1 pol diversity on drug resistance and its clinical implications. Curr Opin Infect Dis 19:594–606PubMedCrossRefGoogle Scholar
  40. King NM, Melnick L, Prabu-Jeyabalan M, Nalivaika EA, Yang SS, Gao Y, Nie X, Zepp C, Heefner DL, Schiffer CA (2002) Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1protease. Protein Sci 11:418–429PubMedCrossRefGoogle Scholar
  41. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, Hayden FG, Sugaya N, Kawaoka Y (2004) Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364:759–765PubMedCrossRefGoogle Scholar
  42. Kleim JP, Rösner M, Winkler I, Paessens A, Kirsch R, Hsiou Y, Arnolds E, Riess G (1996) Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74 -> Val or Ile and Val-75 - > Leu or Ile) HIV-1 mutants. Proc Natl Acad Sci USA 93:34–38PubMedCrossRefGoogle Scholar
  43. Kukolj G, McGibbon GA, McKercher G, Marquis M, Lefebvre S, Thauvette L, Gauthier J, Goulet S, Poupart MA, Beaulieu PL (2005) Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase. J Biol Chem 280:39260–39267PubMedCrossRefGoogle Scholar
  44. Labrosse B, Morand-Joubert L, Goubard A, Rochas S, Labernardiere JL, Pacanowski J, Meynard JL, Hance AJ, Clavel F, Mammano F (2006) Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients. J Virol 80:8807–8819PubMedCrossRefGoogle Scholar
  45. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej N, Naoumov NV, di Bisceglie AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Constance BF, Brown NA (2007) Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 357:2576–2588PubMedCrossRefGoogle Scholar
  46. Landman R, Descamps D, Peytavin G, Trylesinski A, Katlama C, Girard PM, Bonnet B, Yeni P, Bentata M, Michelet C, Benalycherif A, Brun VF, Miller MD, Flandre P (2005) Early virologic failure and rescue therapy of tenofovir, abacavir, and lamivudine for initial treatment of HIV-1 infection: TONUS study. HIV Clin Trials 6:291–301PubMedCrossRefGoogle Scholar
  47. Lanier ER, Hazen R, Ross L, Freeman A, Harvey R (2005) Lack of antagonism between abacavir, lamivudine, and tenofovir against wild-type and drug-resistant HIV-1. J Acquir Immune Defic Syndr 39:519–522PubMedGoogle Scholar
  48. Le PS, Jiang WR, Leveque V, Rajyaguru S, Ma H, Kang H, Jiang S, Singer M, Ali S, Klumpp K, Smith D, Symons J, Cammack N, Najera I (2006a) In vitro selected Con1 subgenomic replicons resistant to 2′-C-methyl-cytidine or to R1479 show lack of cross resistance. Virol 351:349–359CrossRefGoogle Scholar
  49. Le PS, Kang H, Harris SF, Leveque V, Giannetti AM, Ali S, Jiang WR, Rajyaguru S, Tavares G, Oshiro C, Hendricks T, Klumpp K, Symons J, Browner MF, Cammack N, Najera I (2006b) Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus. J Virol 80:6146–6154CrossRefGoogle Scholar
  50. Lecossier D, Shulman NS, Morand-Joubert L, Shafer RW, Joly V, Zolopa AR, Clavel F, Hance AJ (2005) Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine. J Acquir Immune Defic Syndr 38:37–42PubMedCrossRefGoogle Scholar
  51. Leigh Brown AJ (1997) Analysis of HIV-1 env gene sequences reveals evidence for a low effective number in the viral population. Proc Natl Acad Sci USA 94:1862–1865CrossRefGoogle Scholar
  52. Leigh Brown AJ, Richman DD (1997) HIV-1: gambling on the evolution of drug resistance? Nat Med 3:268–271CrossRefGoogle Scholar
  53. Lin K, Hazuda D, Otto M, Boucher C, Schooley R, O'Rear J, Kempf D, Kwong A, Parkin N, for the HCV Drug Resistance Advisory Group (2007) Initial recommendations for HCV drug resistance analysis: a consensus statement from the HCV Drug Resistance Advisory Group. Glob Antivir J 3:29Google Scholar
  54. Lindenbach BD, Rice CM (2005) Unravelling hepatitis C virus replication from genome to function. Nature 436:933–938PubMedCrossRefGoogle Scholar
  55. Locarnini S, Mason WS (2006) Cellular and virological mechanisms of HBV drug resistance. J Hepatol 44:422–431PubMedCrossRefGoogle Scholar
  56. Lockman S, Shapiro RL, Smeaton LM, Wester C, Thior I, Stevens L, Chand F, Makhema J, Moffat C, Asmelash A, Ndase P, Arimi P, van WE, Mazhani L, Novitsky V, Lagakos S, Essex M (2007) Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 356:135–147PubMedCrossRefGoogle Scholar
  57. Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, Liaw YF, Mizokami M, Kuiken C (2007) Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 46:254–265PubMedCrossRefGoogle Scholar
  58. Lu L, Dekhtyar T, Masse S, Pithawalla R, Krishnan P, He W, Ng T, Koev G, Stewart K, Larson D, Bosse T, Wagner R, Pilot-Matias T, Mo H, Molla A (2007) Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitro. Antiviral Res 76:93–97PubMedCrossRefGoogle Scholar
  59. Luber AD (2005) Genetic barriers to resistance and impact on clinical response. MedGenMed 7:69PubMedGoogle Scholar
  60. Maguire MF, Guinea R, Griffin P, Macmanus S, Elston RC, Wolfram J, Richards N, Hanlon MH, Porter DJ, Wrin T, Parkin N, Tisdale M, Furfine E, Petropoulos C, Snowden BW, Kleim JP (2002)Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro. J Virol 76:7398–7406PubMedCrossRefGoogle Scholar
  61. Mammano F, Petit C, Clavel F (1998) Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J Virol 72:7632–7637PubMedGoogle Scholar
  62. Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F, Houghton M (2007) The way forward in HCV treatment–finding the right path. Nat Rev Drug Discov 6:991–1000PubMedCrossRefGoogle Scholar
  63. Meyer PR, Matsuura SE, Mohsin Mian A, So AG, Scott WA (1999) A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse tran-scriptase. Mol Cell 4:35–43PubMedCrossRefGoogle Scholar
  64. Migliaccio G, Tomassini JE, Carroll SS, Tomei L, Altamura S, Bhat B, Bartholomew L, Bosserman MR, Ceccacci A, Colwell LF, Cortese R, De FR, Eldrup AB, Getty KL, Hou XS, LaFemina RL, Ludmerer SW, MacCoss M, McMasters DR, Stahlhut MW, Olsen DB, Hazuda DJ, Flores OA (2003)Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J Biol Chem 278:49164–49170PubMedCrossRefGoogle Scholar
  65. Mink M, Mosier SM, Janumpalli S, Davison D, Jin L, Melby T, Sista P, Erickson J, Lambert D, Stanfield-Oakley SA, Salgo M, Cammack N, Matthews T, Greenberg ML (2005) Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J Virol 79:12447–12454PubMedCrossRefGoogle Scholar
  66. Mo H, Lu L, Pilot-Matias T, Pithawalla R, Mondal R, Masse S, Dekhtyar T, Ng T, Koev G, Stoll V, Stewart KD, Pratt J, Donner P, Rockway T, Maring C, Molla A (2005) Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro. Antimicrob Agents Chemother 49:4305–4314PubMedCrossRefGoogle Scholar
  67. Najera I, Richman DD, Olivares I, Rojas JM, Peinado MA, Perucho M, Najera R, Lopez Galindez C (1994) Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates. AIDS Res Hum Retroviruses 10:1479–1488PubMedCrossRefGoogle Scholar
  68. Nijhuis M, Boucher CAB, Schipper P, Leitner T, Schuurman R, Albert J (1998) Stochastic processes strongly influence HIV-1 evolution during suboptimal protease inhibitor therapy. Proc Natl Acad Sci USA 95:14441–14446PubMedCrossRefGoogle Scholar
  69. Nijhuis M, Schuurman R, de Jong D, Erickson J, Gustchina E, Albert J, Schipper P, Gulnik S, Boucher CAB (1999) Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 13:2349–2359PubMedCrossRefGoogle Scholar
  70. Nijhuis M, van Maarseveen NM, Lastere S, Schipper P, Coakley E, Glass B, Rovenska M, de JD, Chappey C, Goedegebuure IW, Heilek-Snyder G, Dulude D, Cammack N, Brakier-Gingras L, Konvalinka J, Parkin N, Krausslich HG, Brun-Vezinet F, Boucher CA (2007) A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med 4:e36PubMedCrossRefGoogle Scholar
  71. Ono SK, Kato N, Shiratori Y, Kato J, Goto T, Schinazi RF, Carrilho FJ, Omata M (2001) The poly- merase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 107:449–455PubMedCrossRefGoogle Scholar
  72. Pawlotsky JM, Chevaliez S, McHutchison JG (2007) The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 132:1979–1998PubMedCrossRefGoogle Scholar
  73. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, Tian H, Smith D, Winslow GA, Capon DJ, Whitcomb JM (2000) A novel phenotypic drug susceptibility assay for HIV-1. Antim Ag Chemoth 44:920–928CrossRefGoogle Scholar
  74. Podzamczer D, Ferrer E, Gatell JM, Niubo J, Dalmau D, Leon A, Knobel H, Polo C, Iniguez D, Ruiz I (2005) Early virological failure with a combination of tenofovir, didanosine and efavirenz. Antivir Ther 10:171–177PubMedGoogle Scholar
  75. Prado JG, Wrin T, Beauchaine J, Ruiz L, Petropoulos CJ, Frost SD, Clotet B, D'Aquila RT, Martinez-Picado J (2002) Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity. AIDS 16:1009–1017PubMedCrossRefGoogle Scholar
  76. Quinones-Mateu ME, Arts EJ (2001) HIV-1 fitness: implications for drug resistance, disease progression an global epidemic evolution. In: Kuiken C, Foley B, Hahn B, Marx PA, McCutchan F, Mellors J (eds) HIV sequence compendium 2001. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NMGoogle Scholar
  77. Rameix-Welti MA, Agou F, Buchy P, Mardy S, Aubin JT, Veron M, van der WS, Naffakh N (2006) Natural variation can significantly alter the sensitivity of influenza A (H5N1) viruses to oseltamivir. Antimicrob Agents Chemother 50:3809–3815PubMedCrossRefGoogle Scholar
  78. Ruane PJ, DeJesus E (2004) New nucleoside/nucleotide backbone options: a review of recent studies. J Acquir Immune Defic Syndr 37 Suppl 1:S21–S29PubMedGoogle Scholar
  79. Sarafianos SG, Das K, Clark AD Jr, Ding J, Boyer PL, Hughes SH, Arnold E (1999) Lamivu-dine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with β-branched amino acids. Proc Natl Acad Sci USA 96:10027–10032PubMedCrossRefGoogle Scholar
  80. Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Muh U, Welker M, Wincheringer D, Zhou Y, Chu HM, Lin C, Weegink C, Reesink H, Zeuzem S, Kwong AD (2007) Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132:1767–1777PubMedCrossRefGoogle Scholar
  81. Shaw T, Bartholomeusz A, Locarnini S (2006) HBV drug resistance: mechanisms, detection and interpretation. J Hepatol 44:593–606PubMedCrossRefGoogle Scholar
  82. Sheldon J, Rodes B, Zoulim F, Bartholomeusz A, Soriano V (2006) Mutations affecting the replication capacity of the hepatitis B virus. J Viral Hepat 13:427–434PubMedCrossRefGoogle Scholar
  83. SPREAD Programme (2008) Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS 22:625–635Google Scholar
  84. Staschke KA, Colacino JM, Baxter AJ, Air GM, Bansal A, Hornback WJ, Munroe JE, Laver WG (1995) Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en. Virol 214:642–646CrossRefGoogle Scholar
  85. Tai CY, Escarpe PA, Sidwell RW, Williams MA, Lew W, Wu H, Kim CU, Mendel DB (1998) Characterization of human influenza virus variants selected in vitro in the presence of the neu-raminidase inhibitor GS 4071. Antimicrob Agents Chemother 42:3234–3241PubMedGoogle Scholar
  86. Thomson MM, Najera R (2005) Molecular epidemiology of HIV-1 variants in the global AIDS pandemic: an update. AIDS Rev 7:210–224PubMedGoogle Scholar
  87. Tomei L, Altamura S, Bartholomew L, Biroccio A, Ceccacci A, Pacini L, Narjes F, Gennari N, Bisbocci M, Incitti I, Orsatti L, Harper S, Stansfield I, Rowley M, De FR, Migliaccio G (2003) Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J Virol 77:13225–13231PubMedCrossRefGoogle Scholar
  88. Tomei L, Altamura S, Bartholomew L, Bisbocci M, Bailey C, Bosserman M, Cellucci A, Forte E, Incitti I, Orsatti L, Koch U, De FR, Olsen DB, Carroll SS, Migliaccio G (2004) Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides. J Virol 78:938–946PubMedCrossRefGoogle Scholar
  89. Tong X, Chase R, Skelton A, Chen T, Wright-Minogue J, Malcolm BA (2006) Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 70:28–38PubMedCrossRefGoogle Scholar
  90. Warner N, Locarnini S, Kuiper M, Bartholomeusz A, Ayres A, Yuen L, Shaw T (2007) The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. Antimicrob Agents Chemother 51:2285–2292PubMedCrossRefGoogle Scholar
  91. Weinstock HS, Zaidi I, Heneine W, Bennett D, Garcia-Lerma JG, Douglas JM Jr, LaLota M, Dickinson G, Schwarcz S, Torian L, Wendell D, Paul S, Goza GA, Ruiz J, Boyett B, Kaplan JE (2004) The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 189:2174–2180PubMedCrossRefGoogle Scholar
  92. Wensing AM, Boucher CA (2003) Worldwide transmission of drug-resistant HIV. AIDS Rev 5:140–155PubMedGoogle Scholar
  93. Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, Ipe D, Mills RG, Ward P (2001) Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 20:127–133PubMedCrossRefGoogle Scholar
  94. Wolfs TF, Zwart G, Bakker M, Goudsmit J (1992) HIV-1 genomic RNA diversification following sexual and parenteral virus transmission. Virol 189:103–110CrossRefGoogle Scholar
  95. Yi M, Tong X, Skelton A, Chase R, Chen T, Prongay A, Bogen SL, Saksena AK, Njoroge FG, Veselenak RL, Pyles RB, Bourne N, Malcolm BA, Lemon SM (2006) Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations. J Biol Chem 281:8205–8215PubMedCrossRefGoogle Scholar
  96. Zhang Y-M, Imamichi H, Imamichi T, Lane HC, Falloon J, Vasudevachari MB, Salzman NP (1997) Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its gag substrate cleavage sites. J Virol 71:6662–6670PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  • M. Nijhuis
    • 1
  • N.M. van Maarseveen
    • 1
  • C.A.B. Boucher
    • 1
  1. 1.Department of Medical MicrobiologyUniversity Medical Center UtrechtUtrechtThe Netherlands

Personalised recommendations